SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    RiesL, EisnerM, KosaryC, et al. eds. SEER Cancer Statistics Review, vol 2007, 1975-2001. Bethesda, Md: National Cancer Institute; 2005.
  • 2
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
  • 3
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004; 54: 8-29.
  • 4
    Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999; 17: 2365-2370.
  • 5
    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996; 14: 1718-1729.
  • 6
    Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat. 1997; 43: 183-190.
  • 7
    Collichio F, Pandya K. Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival. Oncology (Williston Park). 1994; 8: 45-52.
  • 8
    Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 1998; 16: 501-514.
  • 9
    Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004; 22: 4174-4183.
  • 10
    Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002; 9: 466-472.
  • 11
    Burstein HJ, Winer EP. Reproductive issues. In: HarrisJR, ed. Diseases of the Breast. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000: 1051-1059.
  • 12
    Walshe J, Denduluri N, Swain S. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006; 24: 5769-5779.
  • 13
    Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986; 1: 105-109.
  • 14
    Valagussa P, De Candis D, Antonelli G, Bonadonna G. VIII. Women's health perception and breast cancer: issues of fertility, hormone substitution, and cancer prevention. Recent Results Cancer Res. 1996; 140: 277-283.
  • 15
    Weber B, Luporsi E. Ovarian toxicity of breast cancer chemotherapy [abstract]. Eur J Cancer. 1998; 34( suppl 5): S42.
  • 16
    Colleoni M, Rotmensz N, Peruzzotti G, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006; 17: 1497-1503.
  • 17
    Di Cosimo S, Alimonti A, Ferretti G, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol. 2004; 15: 1065-1071.
  • 18
    Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005; 104: 1575-1579.
  • 19
    Kramer R, Tham Y, Sexton K, Friedman L, Weiss H. Chemotherapy-induced amenorrhea is increased in patients treated with adjuvant doxorubicin and cyclophosphamide (AC) followed by a taxane (T). 2005 ASCO Annual Meeting Proceedings [abstract]. J Clin Oncol. 2005; 23( part I of II; June 1 suppl): 16S. Abstract651.
  • 20
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
  • 21
    Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006; 24: 1045-1051.
  • 22
    Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352: 2302-2313.
  • 23
    Oktay K, Libertella B, Oktem O, et al. The impact of paclitaxel on menstrual function. Breast Cancer Res Treat 2005; 94( suppl): 271s-272s.
  • 24
    Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA 5. J Clin Oncol. 2005; 23: 6002-6008.
  • 25
    Roche H, Spielmann M, Fumoleau P, et al. Safety analysis of the PACS 01 adjuvant trial comparing 6 cycles of FEC 100 followed by 3 cycles of docetaxel (Taxotere) for node positive breast cancer [abstract]. Breast Cancer Res Treat. 2003; 82. S32. Abstract 144.
  • 26
    Samuelkutty S, Gluz O, Mohrmann S. Chemotherapy-induced amenorrhea (CIA) in patients treated with adjuvant CEF/CMF or EC/docetaxel: analysis from a phase III randomized EC/Doc Trial [abstract]. Breast Cancer Res Treat. 1005; 94( S105). Abstract 2063.
  • 27
    Stone ER, Slack RS, Novielli A, et al. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant Adriamycin and Cytoxan (AC) and Adriamycin and Cytoxan followed by Taxol (AC+T) in early stage breast cancer [abstract]. Breast Cancer Res Treat. 2000; 64: 61. Abstract 224.
  • 28
    Ibrahim NK, Macneil S, Headley J, et al. Effect of paclitaxel (P)-based chemotherapy on the ovarian failure (OF) of breast cancer patients (pts): a retrospective study [abstract]. Proc Am Soc Clin Oncol. 2003; 22. Abstract 3029.
  • 29
    Alton J, Jacobs L, Fox K, et al. Chemotherapy-related amenorrhea (CRA) in breast cancer survivors: impact of taxanes on ovarian function [abstract]. Breast Cancer Res Treat. 2004; 88( suppl 1): 61s. Abstract 1060.
  • 30
    Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21: 1431-1439.
  • 31
    Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005; 97: 1724-1733.
  • 32
    Morris SR, Carey LA. Trastuzumab and beyond: new possibilities for the treatment of HER2-positive breast cancer. Oncology (Williston Park). 2006; 20: 1763-1771; discussion 1771-1772, 1774-1776.
  • 33
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
  • 34
    Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008; 90: 1635-1639.
  • 35
    Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Ferti Steril. 2009 Apr 29 Epub ahead of print.